ARS Pharmaceuticals Inc.
SPRY | NASDAQ
$4.35
+$0.24 (+5.84%)
At close: Sep 21, 2026, 4:00 PM ET
$4.46
+$0.11 (+2.53%)
Pre-market:
Sep 22, 2026, 8:07 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -6.70 | 127.88 | -9.61 | -9.80 | -9.51 | -1.51K |
PEG Ratio | 0 | -1.12 | 0.28 | -0.40 | 0 | 15.77 |
PS Ratio | 13.63 | 11.47 | 17.39K | 258.99 | 34.92 | 90.16 |
PB Ratio | 10.05 | 3.98 | 2.26 | 1.25 | -6.15 | -114.44 |
P/FCF Ratio | -6.71 | 78.76 | -8.78 | -8.46 | -10.92 | 197.21 |
P/OCF Ratio | -6.72 | 75.49 | -8.80 | -8.50 | -10.95 | 177.27 |
OCF/S Ratio | -202.74 | 15.20 | -197.55K | -3.05K | -318.94 | 50.86 |
Debt / Equity Ratio | 0.84 | 0 | 0 | 0 | -0.29 | -0.71 |
Quick Ratio | 7.06 | 14.04 | 96.85 | 51.01 | 7.42 | 3.21 |
Current Ratio | 7.28 | 14.26 | 96.85 | 51.01 | 7.42 | 3.21 |
Asset Turnover | 0.26 | 0.25 | 0 | 0 | 0.09 | 0.68 |
Interest Coverage | -69.05 | n/a | n/a | n/a | -183.53 | -16.17 |
Return on Equity | -149.92% | 3.11% | -23.56% | -12.71% | 64.74% | 7.58% |
Return on Assets | -52.28% | 2.28% | -23.31% | -12.32% | -32.94% | -4.03% |
Return on Invested Capital | -62.17% | -0.91% | -29.23% | -12.86% | -34.20% | -2.26% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 75.77% | 76.94% | 100% | -1.2K% | 96.13% | 21.11% |
Net Profit Margin | -203.25% | 8.97% | -181.22K% | -2.64K% | -367.65% | -5.97% |
Pretax Profit Margin | -203.35% | 9.29% | -181.22K% | -2.64K% | -367.65% | -5.97% |
Operating Profit Margin | -212.92% | -3.46% | -225.07K% | -2.7K% | -353.32% | -2.63% |
FCF Margin | -203.14% | 14.57% | -198.14K% | -3.06K% | -319.94% | 45.72% |
EBITDA Margin | -198.64% | 9.38% | -180.97K% | -2.61K% | -361.86% | -2.60% |
Add to Watchlist
Select watchlists to add or remove SPRY